Role of the CHADS 2 Score in Acute Coronary Syndromes

Poçi, Dritan; Hartford, Marianne; Karlsson, Thomas; Herlitz, Johan; Edvardsson, Nils; Caidahl, Kenneth

doi:10.1378/chest.11-0435

Cited by 101 publications

(49 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study has several strengths, and differs from previous studies 10, 22. For instance, the present study is the first to show the association of high CHA 2 DS 2 ‐VASc score with high all‐cause mortality in HF patients, under consideration of several confounders and background, using multivariable analyses and subgroup analyses.…”

Section: Discussionmentioning

confidence: 74%

“…In recent years, the use of the CHA 2 DS 2 ‐VASc score in predicting ischemic stroke, thromboembolism, and death has extended beyond the originally proposed AF field 8, 9. It has been reported that high CHA 2 DS 2 ‐VASc score are associated with mortality in patients with acute coronary syndrome,10 irrespective of the presence or absence of AF. However, the impact of CHA 2 DS 2 ‐VASc score on mortality in HF patients remains unclear.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The CHA₂DS₂‐VASc score as a predictor of high mortality in hospitalized heart failure patients

et al. 2016

View full text Add to dashboard Cite

AimsAtrial fibrillation (AF) is common in patients with heart failure (HF). CHA2DS2‐VASc score was originally employed as a risk assessment tool for stroke in patients with AF; however, it has recently been used to predict not only stroke but also various cardiovascular diseases beyond the original AF field. We aimed to verify the CHA2DS2‐VASc score as a risk assessment tool to predict mortality in patients with HF.Methods and ResultsConsecutive 1011 patients admitted for treatment of HF were divided into three groups based on their CHA2DS2‐VASc scores: score 1–3 group (n = 317), score 4–6 group (n = 549) and score 7–9 group (n = 145). Of the 1011 HF patients, 387 (38.3%) had AF. We compared patient characteristics among the three groups and prospectively followed for all‐cause mortality. Although left ventricular ejection fraction was similar among all three groups, all‐cause mortality was higher in the score 4–6 group and score 7–9 group than in the score 1–3 group (37.9 and 29.3% vs. 15.1%, log‐rank P < 0.001). In the multivariable Cox proportional hazard analysis, the CHA2DS2‐VASc score 7–9 was an independent predictor of all‐cause mortality (all HF patients: hazard ratio (HR) 1.822, P = 0.011; HF patients with AF: HR 1.951, P = 0.031; HF patients without AF: HR 2.215, P = 0.033).ConclusionsThe CHA2DS2‐VASc score was an independent predictor of all‐cause mortality in HF patients with or without AF. This comprehensive risk assessment score may help identify HF patients who are at high risk for mortality in HF patient.

show abstract

Section: Discussionmentioning

confidence: 74%

Section: Introductionmentioning

confidence: 99%

The CHA₂DS₂‐VASc score as a predictor of high mortality in hospitalized heart failure patients

et al. 2016

View full text Add to dashboard Cite

show abstract

“…The relationships between two continuousvariableswereassessedusingabivariatecorrelation method(Pearson'scorrelation).Subsequently,variables found to be significantly correlated in the univariate analysiswerefurtheranalyzedusingaforwardmultifibrillation(AF) [13][14] .PatientswithAFhaveanaverage annualriskofstrokeofapproximately5% 13,15) .There is a direct relationship between the CHADS2 score and the annual risk of stroke in AF patients treated without aspirin or warfarin therapy 14) . In addition, recentresearchhasextendedtheuseoftheCHADS2 score to non-AF populations [16][17] . Welles et al reportedthatthescorecanbeusedtopredictischemic stroke/transientischemicaccidentsinnon-AFsubjects withcoronaryheartdisease 16) .Pociet alalsoshowed that,inpatientswithacutecoronarysyndromewithout AF, the score is significantly associated with allcause mortality 17) .…”

Section: Discussionmentioning

confidence: 99%

“…In addition, recentresearchhasextendedtheuseoftheCHADS2 score to non-AF populations [16][17] . Welles et al reportedthatthescorecanbeusedtopredictischemic stroke/transientischemicaccidentsinnon-AFsubjects withcoronaryheartdisease 16) .Pociet alalsoshowed that,inpatientswithacutecoronarysyndromewithout AF, the score is significantly associated with allcause mortality 17) . Because congestive heart failure, hypertension, an old age, diabetes and stroke are all riskfactorsforPAOD [6][7][8][9][10][11][12] ,theCHADS2scoreshould haveastrongcorrelationwiththeincidenceofPAOD.…”

Section: Discussionmentioning

confidence: 99%

Association between the CHADS2 Score and an Ankle-Brachial Index of ＜0.9 in Patients without Atrial Fibrillation

Hsu

Lin

Lee

et al. 2014

JAT

View full text Add to dashboard Cite

Aim:The ankle-brachial index (ABI) is an easy-to-use, non-invasive and reliable diagnostic tool for assessing peripheral arterial occlusive disease (PAOD). The CHADS2 (congestive heart failure, hypertension, age ≧75 years, diabetes, prior stroke) score is a simple and popular clinical parameter that is used to assess the risk of stroke in patients with atrial fibrillation (AF). Because all five components of the CHADS2 score are risk factors for PAOD, the score should have a strong correlation with the presence of PAOD. However, there are limited studies regarding the association between the CHADS2 score and PAOD in patients without AF. Therefore, the aim of the present study was to investigate whether the CHADS2 score is positively associated with PAOD in patients without AF. Methods: A total of 1,320 patients without AF were included in this study. The ABI was measured using an ABI-form device. PAOD was defined as an ABI of ＜0.9 in either leg. Results: Among the 1,320 subjects (mean age: 60.3±13.4 years), the prevalence of an ABI of ＜0.9 was 5.7%. A multivariate analysis showed that an increased age (odds ratio [OR], 1.054; p＜0.001), decreased estimated glomerular filtration rate (OR, 0.971; p＜0.001) and increased CHADS2 score (OR, 1.861; p＜0.001) were independently associated with an ABI of ＜0.9. Conclusions: Our study demonstrated that the CHADS2 score is significantly associated with an ABI of ＜0.9 in non-AF patients. Further prospective studies are needed to examine the ability of the CHADS2 score to predict the incidence of PAOD. J Atheroscler Thromb, 2014; 21:322-328.

show abstract

“…The application of CHA 2 DS 2 ‐VASc score in patients without AF is relatively new and only a few non‐AF studies have explored this simple method of risk assessment 3, 4, 5…”

Section: Introductionmentioning

confidence: 99%

Risk Stratification Using the CHA ₂ DS ₂ ‐VASc Score in Takotsubo Syndrome: Data From the Takotsubo Italian Network

Parodi

Scudiero

Citro

et al. 2017

JAHA

View full text Add to dashboard Cite

BackgroundThe CHA2DS2‐VASc score predicts stroke in patients with atrial fibrillation and has been reported to have a prognostic role even in acute coronary syndrome patients. The Takotsubo syndrome is a condition that mimics acute coronary syndrome and may present several complications including stroke. We sought to assess the ability of CHA2DS2‐VASc score to predict adverse events in Takotsubo syndrome patients.Methods and ResultsOverall, 371 Takotsubo syndrome patients were enrolled in a prospective registry. Patients were divided into 3 groups according to the CHA2DS2‐VASc score: Group A (≤1), B (2–3), and C (≥4). The median CHA2DS2‐VASc score was 3 (interquartile range: 2–4). Overall, 9%, 42%, and 49% were included in Group A, B, and C, respectively. Follow‐up length was 26±20 months. The mortality rate was 6%, 7%, and 17% in Group A, B, and C, respectively (P=0.011). The stroke rate was 3% and not different among the 3 groups. Estimated major adverse cardiac and cerebrovascular events (the composite of death, myocardial infarction, and stroke) rates in the 3 groups were 6%, 9%, and 17% in Group A, B, and C, respectively (P=0.033). The CHA2DS2‐VASc score resulted as a predictor of major adverse cardiac and cerebrovascular events (odds ratio 2.1, 95% confidence interval, 1.2–3.6; P=0.01) and all‐cause mortality (odds ratio 1.5, 95% confidence interval, 1.2–1.9; P=0.001).ConclusionsIn Takotsubo syndrome, the CHA2DS2‐VASc score allows prediction of cardiovascular events and mortality at long‐term follow‐up.

show abstract

Role of the CHADS 2 Score in Acute Coronary Syndromes

Cited by 101 publications

References 27 publications

The CHA₂DS₂‐VASc score as a predictor of high mortality in hospitalized heart failure patients

The CHA₂DS₂‐VASc score as a predictor of high mortality in hospitalized heart failure patients

Association between the CHADS2 Score and an Ankle-Brachial Index of ＜0.9 in Patients without Atrial Fibrillation

Risk Stratification Using the CHA ₂ DS ₂ ‐VASc Score in Takotsubo Syndrome: Data From the Takotsubo Italian Network

Contact Info

Product

Resources

About

Role of the CHADS 2 Score in Acute Coronary Syndromes

Cited by 101 publications

References 27 publications

The CHA2DS2‐VASc score as a predictor of high mortality in hospitalized heart failure patients

The CHA2DS2‐VASc score as a predictor of high mortality in hospitalized heart failure patients

Association between the CHADS2 Score and an Ankle-Brachial Index of ＜0.9 in Patients without Atrial Fibrillation

Risk Stratification Using the CHA 2 DS 2 ‐VASc Score in Takotsubo Syndrome: Data From the Takotsubo Italian Network

Contact Info

Product

Resources

About

The CHA₂DS₂‐VASc score as a predictor of high mortality in hospitalized heart failure patients

The CHA₂DS₂‐VASc score as a predictor of high mortality in hospitalized heart failure patients

Risk Stratification Using the CHA ₂ DS ₂ ‐VASc Score in Takotsubo Syndrome: Data From the Takotsubo Italian Network